MAP2K7 and Splenomegaly: Combination of JAK and MEK inhibitors resulted in suppression of ERK activity in both JAK2V617F and MPLW515L mouse models, reducing splenomegaly and fibrosis, and improving overall efficacy as compared to JAK inhibition alone27.